Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.


Journal Article

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab. The complete version of the NCCN Guidelines for Bladder Cancer addresses additional aspects of the management of bladder cancer, including non-muscle-invasive urothelial bladder cancer and nonurothelial histologies, as well as staging, evaluation, and follow-up.

Full Text

Duke Authors

Cited Authors

  • Spiess, PE; Agarwal, N; Bangs, R; Boorjian, SA; Buyyounouski, MK; Clark, PE; Downs, TM; Efstathiou, JA; Flaig, TW; Friedlander, T; Greenberg, RE; Guru, KA; Hahn, N; Herr, HW; Hoimes, C; Inman, BA; Jimbo, M; Kader, AK; Lele, SM; Meeks, JJ; Michalski, J; Montgomery, JS; Pagliaro, LC; Pal, SK; Patterson, A; Plimack, ER; Pohar, KS; Porter, MP; Preston, MA; Sexton, WJ; Siefker-Radtke, AO; Sonpavde, G; Tward, J; Wile, G; Dwyer, MA; Gurski, LA

Published Date

  • October 2017

Published In

Volume / Issue

  • 15 / 10

Start / End Page

  • 1240 - 1267

PubMed ID

  • 28982750

Pubmed Central ID

  • 28982750

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2017.0156


  • eng

Conference Location

  • United States